Page 234 - Mercy MOR All Regions_FinalwithVideo

Key Performance Indicators Metric 18.4% Budget $1,209 Variance -0.3% % Variance -0.4% $17,182,561
St. Elizabeth Boardman Hospital
Prior
Actual
$3,059,032
$49,786
$3,067,505
1.6%
$3,017,719
Supply Expense
$16,438,169
Net Patient Revenue
($73,938)
$16,364,231
-1.6%
18.7%
17.8%
Supply Expense % Net Patient Revenue
($24)
$1,233
$1,260
-2.0%
Supply Expense per EIPA
1,246
1,266
1.6%
20
Total Admissions
1,298
4.0%
5,449
5,138
199
4,939

Total Patient Days
2,429
-3.6%
2,538
2,447
(91)
Total EIPAs

(53)
-32.7%
109

162
IP Surgeries
171
-9.5%
442

OP Surgeries
400
Total Surgeries

541
604
(95)
509
Site Performance Summary (42) -15.7% 370
Boardman came in $16K (.5%) under budget on strong IP volume and soft surgical volumes. Surgical volume fell short of budget by 95
procedures (19%) Drug expense was down $65K (5.8%) to budget on a decrease in Remicade, Xolair and Lexiscan. Overall MedSurg
expense was down $18K (1.9%) with $60K in daVinci robot instrument spend did not exist at the facility same period PY. Implant
expense was down $61K on the aforementioned lower than expected surgical volume. significantly under budget on Significant ENT
volume was noted for the month, with $32K in sinuplasty and drug-eluting sinus stents.
St. Elizabeth Boardman Hospital Leader's Summary
Key Challenges
Significant expense in ENT/Sinus products: Acclarent sinuplasty $19,500 ($11K PY) and Propel
drug-eluting stents $12,375 ($3,975 PY) on increased ENT case volume, 56 vs 44 PY (27%)
Continued increase in Wallflex biliary stents as compared to PY. Component used with ERCP
Med/Surg
procedures, volume tracks with recent trend.
$60K Intuitive Surgical spend, while seems high appears to be appropriate for the volume. Spend
spread over multiple accounts: Imp Other $2,160, Insts. $15,400, MedSurg $42,240 39 total
procedures, $1,533 per robotic procedure
The following drugs experienced a decrease in expense for the period: Remicaid (antirheumatic,
down $45K, 76%), Xolair (respiratory, down $26K, 46%) and Lexiscan (cardiac function testing,
down $21K, 70%)
Rx Solu-Medrol (up $66K, 4,850%), Stelara (up $ 27K, 166%), and Activase (up $ 24K, no purchases
01/2017)
$11,680 urinary neurostimulator was expensed to spinal implant account (device can be used for
multiple purposes beyond spinal column).
$18,573 piece of Strattice biologic hernia mesh used for large contaminated belly case.
Implants
Facility continues to experience total joint savings comapred to prior contract as evidenced by
average total knee replacement expense of $3,858 vs. $4,330 PY
Lab over budget $32K on flu-related test volume, $17K in flu tests were accrued as large shipment
arrived 1/29.
IV sets show a wide variance from budget based on IV catheters and start kits that were
Other Expenses
previously expensed to Med Surg supplies
Actions Taken/Planned:
Review ENT device contribution to margin and number of devices used per procedure.
Continue to closely monito flu item availability and resultant spend. Reduce reorders to coincide
with the end of flu season.
Reviewed Red Cross blood handling process after extreme spikes/credits in expense were
encoutered throughout MHY in Q4, 2017.